Overview

A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis. Condition or disease: Ulcerative Colitis Intervention/treatment: Drug: Etrasimod Drug: Placebo Phase: Phase 3
Phase:
Phase 3
Details
Lead Sponsor:
Everstar Therapeutics Limited